Hospital-Treated Gram-Negative Infections – Epidemiology – Europe Data
Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rates of GNIs for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this content.
Clarivate Epidemiology’s HT GNI forecast will answer the following questions:
Of all people diagnosed with GNIs, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HT GNIs over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:
Diagnosed HCAP events due to E.coli.
Diagnosed BSI events due to Klebsiella.
Diagnosed BSI events due to E.coli.
Diagnosed BSI events due to Pseudomonas.
Diagnosed BSI events due to other gram-negative pathogens.
Hospital-Treated Gram-Negative Infections - Epidemiology - Europe Data
Diagnosed Event Rate of UTIs per 1,000 per Year Among People of All Ages in 2021 and 2031
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Events of UTIs over the Next Ten Yearsttttttttt
Diagnosed UTI Events
Diagnosed NP Events
Diagnosed BSI Events
Diagnosed cIAI Events
Diagnosed cSSSI Events
Diagnosed SSI Events
Gram-Negative Pathogen Distribution
Studies Included in the Analysis of Hospital-Treated Infections
Studies Excluded from the Analysis of Hospital-Treated Infections
Risk/Protective Factors for Hospital-Treated Infections
Mariah J. Scott, M.S., M.P.H.,is an associate epidemiologist at Clarivate. Previously, she investigated patient-reported outcomes on health-related quality of life during the transition from pediatric to adult care in patients with Sickle Cell Disease throughout the state of New Jersey. Ms. Scott received her B.S. in Molecular Biology from Montclair State University and her M.S. from Seton Hall University where she studied Microbiology and Immunology. She also holds an M.P.H. degree in epidemiology from Rutgers University.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.